ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) is to present in vivo data exemplifying the cellular and tissue targeting capabilities and highlighting the significant advantages of its CustomEX drug delivery platform at Cell 2023 in London.
Data to be presented shows the significant improvement in targeting and delivery of payloads that can be achieved through the careful selection of specific exosomes from different cell sources, said the company.
ReNeuron added the CustomEX platform offers this ability to select the exosome cell type for a partner's need and the payload/target cell of their choice.
Iain Ross, executive chairman, commented: "Since restructuring the business in January of this year, the ReNeuron team has been focused on generating the critical in vivo data that exemplifies the cellular and tissue targeting capabilities of CustomEX, our exosome drug delivery platform.
“I am very excited about the recent in vivo data that is being presented today at Cell 2023 in London that highlights the significant advantages of CustomEX and differentiates this drug delivery platform from that of our competitors.
“In CustomEX we are developing a leading-edge platform for the targeted delivery of modern-day therapies."
For the six months to end September 2023, ReNeuron generated revenue of £157,000 (£438,000) from partner-funded development activities and royalty income
Losses for the period were £2.8 million (loss £3.2 million) with cash on 30 September of £5.1 million (31 March 2023: £7.2 million).